Insider · CIK 0001373110

Gergen Mark J

Reports to the SEC for 4 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001373110

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-01-08	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−48.1K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−241K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−519K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−342K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−364K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.U Disposition from Tender	Director, President and CEO	UDisposition from Tender	−637K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−173K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−75K sh	—	—	0
2025-01-02	Poseida Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−23.3K sh	$9.60	−$224K	630,726
2024-12-10	Poseida Therapeutics, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+30K sh	$2.78	+$83.4K	681,291
2024-12-10	Poseida Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−30K sh	$9.46	−$284K	651,291
2024-12-10	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−30K sh	—	—	96,372
2024-11-26	Poseida Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−30K sh	$9.27	−$278K	651,291
2024-11-26	Poseida Therapeutics, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+30K sh	$2.78	+$83.4K	681,291
2024-11-26	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−30K sh	—	—	126,372
2024-03-01	Poseida Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−34.2K sh	$4.13	−$141K	651,291
2024-02-01	Poseida Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−47.2K sh	$3.41	−$161K	685,448
2024-01-02	Poseida Therapeutics, Inc.Stock Option (Right to buy)A Award	Director, President and CEO	AAward	+173K sh	—	—	172,600
2024-01-02	Poseida Therapeutics, Inc.A Award	Director, President and CEO	AAward	+125K sh	—	—	732,610
2023-03-01	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+364K sh	—	—	364,060
2023-03-01	Poseida Therapeutics, Inc.A Award	Director, President and CEO	AAward	+270K sh	—	—	601,610
2023-02-01	Poseida Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−31.8K sh	$7.00	−$223K	330,314
2022-02-01	Poseida Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+519K sh	—	—	518,500
2022-02-01	Poseida Therapeutics, Inc.A Award	Director, President and CEO	AAward	+357K sh	—	—	357,200
2021-02-04	Poseida Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+342K sh	—	—	342,000
2020-07-09	Poseida Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+75K sh	—	—	75,000
2017-02-22	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsA Award	SVP, Chief Operating Officer	AAward	+45.6K sh	—	—	45,568
2017-02-22	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockA Award	SVP, Chief Operating Officer	AAward	+72.9K sh	—	—	72,925
2016-09-01	HALOHALOZYME THERAPEUTICS, INC. · Options to Purchase Common StockA Award	SVP, Chief Operating Officer	AAward	+334K sh	—	—	333,890
2016-01-22	Mirati Therapeutics, Inc.Stock Option (Right to Buy)A Award	Executive VP, COO	AAward	+60K sh	—	—	60,000
2016-01-15	Mirati Therapeutics, Inc.M Exercise/Conversion	Executive VP, COO	MExercise/Conversion	+10K sh	$8.50	+$85K	15,748
2016-01-15	Mirati Therapeutics, Inc.M Exercise/Conversion	Executive VP, COO	MExercise/Conversion	+5,000 sh	$8.50	+$42.5K	5,748
2016-01-15	Mirati Therapeutics, Inc.Non Qualified Stock Option (right to buy)M Exercise/Conversion	Executive VP, COO	MExercise/Conversion	+10K sh	$25.92	+$259K	117,000
2016-01-15	Mirati Therapeutics, Inc.Incentive Stock Option (right to buy)M Exercise/Conversion	Executive VP, COO	MExercise/Conversion	+5,000 sh	—	—	127,000
2016-01-15	Mirati Therapeutics, Inc.S Sale	Executive VP, COO	SSale	−10K sh	$25.92	−$259K	5,748
2015-02-04	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Executive VP, COO	AAward	+30K sh	—	—	30,000
2013-07-17	Mirati Therapeutics, Inc.Stock Option (Right to Buy)A Award	Executive VP, COO	AAward	+132K sh	—	—	132,000
2012-08-08	AMYLIN PHARMACEUTICALS INCIncentive Stock Option (right to buy)H Expiration (Short)	SVP, Corporate Development, SVP, Corporate Development	HExpiration (Short)	−2,585 sh	—	—	0
2012-08-08	AMYLIN PHARMACEUTICALS INCIncentive Stock Option (right to buy)J Other	SVP, Corporate Development, SVP, Corporate Development	JOther	−3,439 sh	$31.00	−$107K	0
2012-08-08	AMYLIN PHARMACEUTICALS INCU Disposition from Tender	SVP, Corporate Development, SVP, Corporate Development	UDisposition from Tender	−1,360 sh	$31.00	−$42.2K	0
2012-08-08	AMYLIN PHARMACEUTICALS INCU Disposition from Tender	SVP, Corporate Development, SVP, Corporate Development	UDisposition from Tender	−6,614.4 sh	$31.00	−$205K	1,360
2012-08-08	AMYLIN PHARMACEUTICALS INCNon-Qualified Stock Option (right to buy)J Other	SVP, Corporate Development, SVP, Corporate Development	JOther	−51.6K sh	$31.00	−$1.6M	0
2012-08-08	AMYLIN PHARMACEUTICALS INCU Disposition from Tender	SVP, Corporate Development, SVP, Corporate Development	UDisposition from Tender	−473.3 sh	$31.00	−$14.7K	0
2012-08-08	AMYLIN PHARMACEUTICALS INCU Disposition from Tender	SVP, Corporate Development, SVP, Corporate Development	UDisposition from Tender	−2,135.7 sh	$31.00	−$66.2K	473.3
2012-08-08	AMYLIN PHARMACEUTICALS INCJ Other	SVP, Corporate Development, SVP, Corporate Development	JOther	−53.2K sh	$31.00	−$1.65M	0
2012-08-08	AMYLIN PHARMACEUTICALS INCJ Other	SVP, Corporate Development, SVP, Corporate Development	JOther	+53.2K sh	$31.00	+$1.65M	53,181
2012-08-08	AMYLIN PHARMACEUTICALS INCU Disposition from Tender	SVP, Corporate Development, SVP, Corporate Development	UDisposition from Tender	−412 sh	$31.00	−$12.8K	0
2012-08-08	AMYLIN PHARMACEUTICALS INCU Disposition from Tender	SVP, Corporate Development, SVP, Corporate Development	UDisposition from Tender	−64.3K sh	$31.00	−$1.99M	412
2012-08-08	AMYLIN PHARMACEUTICALS INCIncentive Stock Option (right to buy)J Other	SVP, Corporate Development, SVP, Corporate Development	JOther	−7,533 sh	$31.00	−$234K	0
2012-08-08	AMYLIN PHARMACEUTICALS INCIncentive Stock Option (right to buy)J Other	SVP, Corporate Development, SVP, Corporate Development	JOther	−8,379 sh	$31.00	−$260K	0

Recent filings

Accepted (ET)
Jan 84
Gergen Mark J0001415889-25-001081
SEC(opens sec.gov)
Jan 34
Gergen Mark J0000950170-25-001527
SEC(opens sec.gov)
Dec 114
Gergen Mark J0000950170-24-135466
SEC(opens sec.gov)
Nov 274
Gergen Mark J0000950170-24-131665
SEC(opens sec.gov)
Mar 44
Gergen Mark J0000950170-24-024922
SEC(opens sec.gov)
Feb 24
Gergen Mark J0000950170-24-010943
SEC(opens sec.gov)
Jan 44
Gergen Mark J0000950170-24-001831
SEC(opens sec.gov)
Mar 24
Gergen Mark J0001209191-23-014898
SEC(opens sec.gov)

Companies

Address

9360 TOWNE CENTRE DR

SAN DIEGO, CA, 92121